277 related articles for article (PubMed ID: 1778182)
1. Update on the metabolic effects of steroidal contraceptives.
Sondheimer SJ
Endocrinol Metab Clin North Am; 1991 Dec; 20(4):911-23. PubMed ID: 1778182
[TBL] [Abstract][Full Text] [Related]
2. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
Teichmann A
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
[TBL] [Abstract][Full Text] [Related]
3. [Influence of progestins on adverse effects of oral contraceptives].
Wynn V
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
5. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
6. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
[TBL] [Abstract][Full Text] [Related]
7. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol.
Akerlund M
Acta Obstet Gynecol Scand Suppl; 1997; 164():63-5. PubMed ID: 9225641
[TBL] [Abstract][Full Text] [Related]
9. [Pros and cons of triphasic oral contraception].
Berdah J
Contracept Fertil Sex (Paris); 1985 Dec; 13(12):1205-10. PubMed ID: 12267512
[TBL] [Abstract][Full Text] [Related]
10. [Potential advantages of triphasic combined oral contraceptives in the light of recent epidemiological and endocrinometabolic data].
Gaspard U; Dubois M
Contracept Fertil Sex (Paris); 1982 Sep; 10(9):551-60. PubMed ID: 12311606
[TBL] [Abstract][Full Text] [Related]
11. [The triphasic pill].
Belaisch J
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):368-72. PubMed ID: 12280209
[TBL] [Abstract][Full Text] [Related]
12. [Metabolic risks of oral contraception].
Monier L
Rev Int Pediatr; 1988 Feb; (178):64-5. PubMed ID: 12282576
[TBL] [Abstract][Full Text] [Related]
13. [Progestins and arterial disease].
Rozenbaum H
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):344-52. PubMed ID: 12280205
[TBL] [Abstract][Full Text] [Related]
14. [How to choose an oral contraceptive in 1984].
Rozenbaum H
Contracept Fertil Sex (Paris); 1984 Nov; 12(11):1201-6. PubMed ID: 12266609
[TBL] [Abstract][Full Text] [Related]
15. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
Serfaty D; Wildemeersch D; Verougstraete A; Creatsas G
Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():73-9. PubMed ID: 8574253
[TBL] [Abstract][Full Text] [Related]
16. [Metabolic impact of current estrogen-progestins and cardiovascular consequences].
Gaspard U; Lambotte R
Bull Mem Acad R Med Belg; 1991; 146(8-10):334-42; discussion 342-5. PubMed ID: 1815814
[TBL] [Abstract][Full Text] [Related]
17. [Oral contraception: failures and risks].
Foussard-blanpin O; Paillot-renaud P; Bruneau-bigot A
Lyon Pharm; 1984 Nov; 35(6):385-93. PubMed ID: 12280590
[TBL] [Abstract][Full Text] [Related]
18. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
19. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study.
Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C
Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913
[TBL] [Abstract][Full Text] [Related]
20. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
Godsland IF; Crook D; Devenport M; Wynn V
Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
